^
Association details:
| Biomarker: | ROS1 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ensacove (ensartinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial
Published date:
12/21/2022
Excerpt:
Patients with advanced, ALK or ROS1-positive NSCLC were recruited from 2 centers in China....In all patients (43 ALK+ and 5 ROS1+), the ORR and disease control rates (DCR) were 64.6 % (1 CR and 30 PR) and 81.3% (8 SD), respectively. The median PFS was 16.79 months [95% confidence interval (CI), 8.11 to 25.47 months]….In 43 ALK positive patients, the ORR and DCR were 72.1% (95% CI, 58.1–86.1%) and 83.7% (95% CI, 72.2–95.2%), respectively. The mPFS was 18.23 months (95% CI, 8.77–27.70 months).
DOI:
10.21037/jtd-22-1606
Trial ID:
Source:
Title:
Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study
Published date:
07/12/2021
Excerpt:
Ensartinib had a moderset efficacy in patients with ROS1-positive NSCLC with an acceptable safety profile.
DOI:
doi.org/10.1016/j.jtho.2021.06.023
Trial ID:
